NeuTec wants to make visiting the hospital an experience that lessens patient dangers. The biopharmaceutical company identifies and compares antibodies produced by patients who recover from infections (acquired in hospitals) to those produced by patients who die. Then, using its FabTec technology, it develops genetically recombinant antibodies, or "grabs," to treat patients with life-threatening infections. The company's two leading candidates, Mycograb, which targets a fungus in the mouth and skin, and Aurograb, which targets bacterial infections, are in clinical trials in the UK. Mycograb also is in clinical trials in the US.

BioSpecifics Technologies Corp. company was founded in 1957 and is headquartered in Lynbrook, New York. BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase for multiple indications in the United States. The company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase known as XIAFLEX for clinical indications in dupuytren's disease, peyronie's disease, and frozen shoulder. The XIAFLEX is under phase IIb clinical trial for the treatment of peyronie's disease. BioSpecifics Technologies also focuses on the development of collagenase for various other clinical indications, including lipomas and cellulite.

Abbott Laboratories company was founded in 1888 and is based in Abbott Park, Illinois. Abbott Laboratories manufactures and sells health care products worldwide. Abbott company's Pharmaceutical Products segment offers adult and pediatric pharmaceuticals for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, dyslipidemia, HIV infection, hypothyroidism, advanced prostate cancer, endometriosis and central precocious puberty, anemia caused by uterine fibroids, obesity, epilepsy and bipolar disorder, migraines, and secondary hyperparathyroidism; and provides anesthesia products and anti-infectives. Its Diagnostic Products segment offers immunoassay systems; chemistry systems; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases; instruments that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infections agents; genomic-based tests; hematology systems and reagents; and point-of-care diagnostic systems and tests for blood analysis.Abbott Company's Nutritional Products segment provides various forms of prepared infant formula and follow-on formula, adult and other pediatric nutritional products, nutritional products used in enteral feeding in health care institutions, and bars and nutritional brands. Its Vascular Products segment offers coronary, endovascular, and vessel closure devices, such as drug-eluting coronary stent systems, coronary metallic stents, balloon dilatation products, coronary guidewires, vessel closure devices, and carotid stent systems to treat vascular disease. Abbott serves wholesalers, government agencies, health care facilities, specialty pharmacies, independent retailers, hospitals, clinics, physicians' offices, blood banks, commercial laboratories, alternate-care testing sites, plasma protein therapeutic companies, and third-party distributors.

Solvay Pharmaceuticals is out to solve the medical maladies of the world. Part of Solvay SA's pharmaceuticals division, the US-based company develops, produces, and markets therapies for cardiovascular, gastroenterological, and neurological disorders. Solvay Pharmaceuticals also makes and markets flu vaccines and products for specialized markets such as women's and men's health. Its marketed products include AndroGel (testosterone replacement gel), Marinol (appetite stimulator and antiemetic), and ACEON (an antihypertension drug). Abbott Laboratories has agreed to acquire the Solvay Pharmaceuticals organization. Solvay Pharmaceuticals is led by CEO Stephen Hill.

CyDex Pharmaceuticals, Inc. company was founded in 1993 and is based in Lenexa, Kansas. CyDex Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of drugs specifically designed to address limitations of current therapies. It develops a portfolio of product candidates utilizing its drug formulation technology using Captisol, a group of cyclodextrins. The company’s products include Geodon IM and Abilify Injection IM for bipolar disorder/schizophrenia; Vfend IV for antifungal; and Cerenia for canine motion sickness. It also develops Fosphenytoin IV and IM for status epilepticus; Melphalan IV for multiple myeloma; Topiramate IV for epilepsy; Amiodarone IV for arrhythmia; Budesonide Solution Inhalation for asthma; Clopidogrel IV for atherothrombosis; and Budesonide/Azelastine Nasal Spray for allergic rhinitis. In addition, the company out license its technology to third parties for use in the development of their products. CyDex Pharmaceuticals, Inc. was formerly known as CyDex, Inc. and it changed its name in November 2007.

Vaxon Biotech is a biopharmaceutical company focused on the treatment of cancers and related malignancies. Disease targets include breast, lung, pancreatic, and prostate cancer. The company's claim to fame is its development of optimized cryptic peptide antigens (substances that trigger protein responses in the immune system), which have shown early progress in the immune response against these cancers. The company's development products are classified as therapeutic vaccines and are developed to trigger the immune system to attack malignant cells in solid tumors while steering clear from normal cells.

BioTrove, researchers can mine the treasure trove of information encoded in genetic material... and still make it home in time for dinner. The company makes the OpenArray life science research systems that allow scientists to rapidly prepare and test multiple genetic samples at once. The system can perform more than 3,000 genetic tests simultaneously on a single slide and is used by laboratory researchers in gene expression and genotyping analysis. BioTrove was acquired by Life Technologies in late 2009. At the same time, the company's RapidFire sample preparation business was spun off into a new entity named BIOCIUS Life Sciences.

Nektar Therapeutics company was founded in 1990 and is headquartered in San Carlos, California. Nektar Therapeutics is a biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. The Company’s product pipeline is comprised of drug candidates across a number of therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology. Nektar’s research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. It creates its drug candidates by using its chemistry platform to modify the chemical structure of drugs using polymer conjugates. Nektar’s drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

American Bio Medica Corporation develops, manufactures, and sells immunoassay diagnostic test kits for the point of collection testing (POCT) for drugs of abuse in North America, Europe, the Asia/Pacific Rim, Africa, and South America. Its products include Rapid Drug Screen, a POCT kit to detect the presence or absence of 2 to 10 drugs of abuse in a single urine specimen; Rapid One, which screens for the presence or absence of a single drug of abuse in a urine specimen; Rapid TEC that contains 1 or 2 drug testing strips to test for 2 to 5 drugs of abuse in a single urine specimen; RDS InCup, a POCT for 2 to 12 drugs of abuse that incorporate collection and testing of sample in a device; Rapid TOX, a drug screen that detects 2 to 10 drugs of abuse in a single urine specimen; and Rapid TOX Cup, a POCT for 2 to 14 drugs of abuse that incorporate collection and testing of sample in a single device.American Bio Medica Corporation company’s products also include OralStat, a POCT system to detect drugs of abuse in oral fluids; OralStat EX, an oral fluid POCT for point of collection testing and confirmation testing; and Rapid STAT, an oral fluid POCT. In addition, it offers Rapid Reader, a compact and portable device that captures a picture of the test results on an ABMC drug screen. Further, American Bio distributes various POCTs to detect the presence or absence of adulterants, alcohol, and nicotine; and provides bulk strip contract manufacturing services to non-affiliated POCT diagnostic companies. It offers products for employers, law enforcement, government, health care, laboratory, and education professionals to test for cocaine, THC, opiates, amphetamines, PCP, benzodiazepines, methamphetamines, barbiturates, tricyclic antidepressants, methadone, oxycodone, propoxyphene, and buprenorphine. The company was formerly known as American Micro Media, Inc and changed its name to American Bio Medica Corporation in September 1992. The company was founded in 1986 and is based in Kinderhook, New York.

Tridelta specialises in the development, manufacturing and marketing of diagnostic products for the animal health care industry. The company has commercialised five technologies to date with its "PHASE" range of Acute Phase Protein Assays, which are indicators of the presence of an inflammatory reaction, detected in the blood before the animal shows any physical signs of ill health. Species of specific interest include: cattle, horses, sheep, cats, dogs, pigs and rodents.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.